LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

Home・Aktien・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Open

4.44 0.91

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.36

Max

4.46

Schlüsselkennzahlen
By Trading Economics
Einkommen	27M 2.5M
Verkäufe	9M 11M
Gewinnspanne	23.494
Angestellte	44
EBITDA	27M 2.6M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	210M 849M
Vorheriger Eröffnungskurs	3.53
Vorheriger Schlusskurs	4.44

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

3.255 / 3.365 Unterstützung & Widerstand

Arbutus Biopharma Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Sept. 2025, 18:25 UTC

Wichtige Markttreiber

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28. Sept. 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28. Sept. 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28. Sept. 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28. Sept. 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27. Sept. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. Sept. 2025, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26. Sept. 2025, 20:54 UTC

Ergebnisse

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26. Sept. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. Sept. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. Sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. Sept. 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26. Sept. 2025, 19:53 UTC

Akquisitionen, Fusionen, Übernahmen

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. Sept. 2025, 19:40 UTC

Ergebnisse

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26. Sept. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26. Sept. 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26. Sept. 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26. Sept. 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26. Sept. 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26. Sept. 2025, 18:50 UTC

Market Talk

Ergebnisse

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26. Sept. 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26. Sept. 2025, 18:02 UTC

Akquisitionen, Fusionen, Übernahmen

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26. Sept. 2025, 18:02 UTC

Akquisitionen, Fusionen, Übernahmen

ING: Global Development Hasn't Received All Necessary Approvals >ING

26. Sept. 2025, 18:02 UTC

Akquisitionen, Fusionen, Übernahmen

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26. Sept. 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26. Sept. 2025, 16:56 UTC

Market Talk

Ergebnisse

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26. Sept. 2025, 16:41 UTC

Market Talk

Ergebnisse

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26. Sept. 2025, 16:26 UTC

Ergebnisse

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26. Sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Arbutus Biopharma Corp Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Arbutus Biopharma Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

3.255 / 3.365Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.